Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 16, 2021

View Archived Issues

MK2 is a therapeutic target in PDAC that mediates resistance to FIRINOX chemotherapy

Targeting cyclophilin A potentiates chemotherapeutic efficacy in chemoresistant colorectal cancer

YES1 seen to induce the growth of TNBC

Kallyope patents AMPK activators

G1 Therapeutics discloses new CDK2 inhibitors

Senda Biosciences presents AhR antagonists for cancer

Aligos Therapeutics identifies new PD-1/PD-L1 interaction inhibitors

Sinocelltech describes method for enhancing immunogenicitiy of Fc-fusion antigen

Tweaking KLF4 enhances cellular reprogramming

Targeting LIF/LIFR axis as potential therapeutic strategy against adiposity-driven TNBC

HLA-DRB1 copy number predicts response to immunosuppressive therapy in acquired aplastic anemia

One-step synthetic approach for the fabrication of oriented antibody-decorated MOF nanocrystals

Nucleoside analogue sangivamycin shows in vitro activity against several variants of SARS-CoV-2

Discovery of long-acting entecavir prodrugs

BridGene and Peter MacCallum Cancer Centre enter research collaboration for ovarian cancer

GALE is a biomarker of inherited thrombocytopenia

SAB-185 neutralizes SARS-CoV-2 Omicron variant in in vitro pseudovirus model

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Sichuan Kelun Pharmaceutical Research Institute discovers GPR6 inverse agonists
BioWorld Science
Sichuan Kelun Pharmaceutical Research Institute Co. Ltd. has identified G protein-coupled receptor 6 (GPR6) inverse agonists reported to be useful for the...